Clinical Thyroidology® for the Public Volume 12

Clinical Thyroidology® for the Public summarizes selected research studies discussed in the previous month’s issue of Clinical Thyroidology, an official publication of the American Thyroid Association®.

Search Clinical Thyroidology® for the Public

 

Volume 12 2019

  • November is Thyroid Nodules Awareness Month

    In this issue Volume 12 Issue 11, the studies ask the following questions:

    1. Does the treatment option of Graves’ disease affect survival?
    2. Do clotting factors play a role in the association between high thyroid levels and heart disease?
    3. Is tocilizmab an effective treatment for Graves’ eye disease?
    4. Is Hashimoto’s thyroiditis a risk factor for thyroid cancer?
    5. Do thyroid cancer survivors with good outcomes continue to worry about their cancer?
    6. Does thyroid hormone treatment affect metabolism?

  • October is Thyroid Nodules Awareness Month

    In this issue Volume 12 Issue 10, the studies ask the following questions:

    1. Do thyroid cancer survivors have a worse quality of life than other cancer survivors?
    2. Do low and intermediate risk thyroid cancer patients still need regular neck ultrasounds?
    3. How fast do small thyroid cancers grow during active surveillance?
    4. Is there any difference in prognosis between focal tall-cell changes and tall-cell variants of papillary cancer?
    5. Is the prognosis for multifocal papillary cancer different than for unifocal cancers?
    6. Are TPO antibodies associated with worse pregnancy outcomes?

  • September is Thyroid Cancer Awareness Month

    In this issue Volume 12 Issue 9, the studies ask the following questions:

    1. Does levothyroxine therapy in TPO-positive women affect miscarriage rates?
    2. Does mild to moderate iodine deficiency in early pregnancy affect IQ in the children?
    3. Is routine thyroid testing in hospitalized children helpful?
    4. Does T3 therapy help recover from heart attacks?
    5. Is long-term methimazole therapy effective in the treatment of toxic nodular goiters?
    6. Is a core needle biopsy helpful in the diagnosis of indeterminate thyroid biopsies?

  • August is Thyroid & Pregnancy Awareness Month

    In this issue Volume 12 Issue 8, the studies ask the following questions:

    1. Does radioactive iodine therapy for Graves’ disease cause cancer?
    2. Is obesity a risk factor for thyroid cancer?
    3. Does bariatric surgery change levothyroxine dose requirements?
    4. Are calcitonin measurements helpful in following patients with medullary thyroid cancer after surgery?
    5. Can cancer drugs make radioactive iodine-resistant thyroid cancer responsive to radioactive iodine again?
    6. How well do current molecular marker tests identify benign nodules that have indeterminate biopsy results?

  • July is Graves' Disease Awareness Month

    In this issue Volume 12 Issue 7, the studies ask the following questions:

    1. Do thyroid antibodies predict relapse in patients with Graves’ disease?
    2. Are side effects of antithyroid drugs more common in patients with
      amiodarone-induced thyrotoxicosis?
    3. Should thyroidectomy be considered in some patients with Hashimoto’s
      thyroiditis?
    4. Are NIFTP tumors really benign?

  • In this issue Volume 12 Issue 6, the studies ask the following questions:

    1. What are the risk factors for a poor prognosis in medullary thyroid cancer?
    2. Can an ultrasound classification system help make a diagnosis of thyroid cancer?
    3. Are the rates of indeterminate nodules different between children and adults?
    4. Does levothyroxine therapy lead to osteoporosis?
    5. Do thyroid antibodies interfere with thyroid function during pregnancy?

  • In this issue Volume 12 Issue 5, the studies ask the following questions:

    1. Is iodine content in prenatal vitamins adequate?
    2. Does adequate levothyroxine therapy in hypothyroid mothers
      improve pregnancy outcomes?
    3. Does treatment of hyperthyroidism affect the risk for cardiac problems?
    4. Does levothyroxine therapy affect the death rate in patients with
      heart failure?
    5. Can low risk thyroid cancers be safely watched without surgery?
    6. Can a new radiology grading system decrease the need for biopsy
      of thyroid nodules discovered on PET scans?

  • In this issue Volume 12 Issue 4, the studies ask the following questions:

    1. Is levothyroxine therapy overused?
    2. Do thyroid disorders affect your sex life?
    3. Does RAI for Graves’ disease adversely affect quality of life?
    4. Are low-income children with hypothyroidism at risk for intellectual disability?
    5. Is levothyroxine therapy helpful to patients with subclinical hypothyroidism undergoing in vitro fertilization?
    6. Is there a risk of secondary cancers after RAI for thyroid cancer?

  • In this issue Volume 12 Issue 3, the studies ask the following questions:

    1. What affects quality of life in thyroid cancer patients?
    2. What drives patients with hypothyroidism to seek alternative therapies?
    3. What factors predict the outcome of RAI therapy in Graves’ disease?
    4. Does RAI therapy for Graves’ disease in women increase the risk of neonatal hyperthyroidism in their babies?
    5. Does individualized RAI therapy dosing have an effect on thyroid cancer outcomes?
    6. Does levothyroxine therapy normalize cholesterol levels in hypothyroid patients?

  • In this issue Volume 12 Issue 2, the studies ask the following questions:

    1. Does treatment of subclinical hypothyroidism help patient symptoms?
    2. Does poor iodine nutrition in pregnant mothers affect the baby?
    3. Does hypothyroidism in pregnant mothers increase the risk of childhood asthma?
    4. Do molecular markers provide information on cancer prognosis?
    5. Does the dose of RAI affect response in patients with low risk thyroid cancer?
    6. Does high dose RAI affect local recurrence rates?

  • In this issue Volume 12 Issue 1, the studies ask the following questions:

    1. Is the increased use of ultrasound the cause of the increase in diagnosis of thyroid cancer?
    2. Does combining cancer staging systems with patient age improve survival predictions for thyroid cancer?
    3. How effective is levatinib in treating patients with advanced thyroid cancer?
    4. Does developing hypothyroidism while taking tyrosine kinase inhibitor drugs for non-thyroidal cancer increase survival?
    5. Who orders rT3 testing in the United States?
    6. Is combination therapy effective for severe Graves’ eye disease?

Clinical Thyroidology® for the Public Past Issues

2014 – 2018

VOLUME 11

VOLUME 10

VOLUME 9

VOLUME 8

VOLUME 7

2011 – 2013

VOLUME 6

VOLUME 5

VOLUME 4

2008 – 2010

VOLUME 3

VOLUME 2

VOLUME 1

Editor
Alan P. Farwell, MD, FACE
Boston Medical Center
Boston University School of Medicine

Editorial Board
Jessie Block-Galaraza, MD, Albany, NY
Gary Bloom, New York, NY
Alina Gavrila, MD, MMSC, Boston, MA
Melanie Goldfarb, MD, MS, FACS, FACE,
Santa Monica, CA
Shirin Haddady, MD, MPH, Boston, MA
Sun Lee, MD, Boston, MA
Joshua Klopper, MD, Denver, CO
Angela Leung, MD, Los Angeles, CA
Priya Mahajan, MD, Houston, TX
Maria Papaleontiou, MD, Ann Arbor, MI
Jason D. Prescott, MD PhD, Baltimore, MD
Marjorie Safran, MD, Worcester, MA
Anna M. Sawka, MD, Toronto, ON, Canada
Phillip Segal, MD, Toronto, ON, Canada
Vibhavsu Sharma, MD, Albany, NY
Ebru Sulanc, MD , Detroit, MI
Valentina Tarasova, MD, Tampa, FL
Whitney Woodmansee, MD, Gainesville, FL

We welcome your feedback and suggestions. Let us know what you want to see in this publication.

Feedback & Suggestions

Published monthly and distributed free of charge to Friends of the ATA

Sign Up Here

Give Direct

IMA Outstanding Achievement Award